Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.

PURPOSE To compare the efficacy of intravitreal aflibercept and ranibizumab on the exudative activity of neovascular age-related macular degeneration (nAMD) using optical coherence tomography (OCT) and to correlate morphologic findings with visual acuity (VA) outcomes. DESIGN Post hoc analysis of the prospective VIEW trials. PARTICIPANTS Data of 1815 patients randomized to 0.5 mg ranibizumab every 4 weeks (Q4wks), 2 mg aflibercept Q4wks, or 2 mg aflibercept every 8 weeks (Q8wks). METHODS Standardized OCT evaluation was performed by masked reading centers for the presence of intraretinal cystoid fluid (IRC), subretinal fluid (SRF), and pigment epithelial detachment (PED). Rates of feature resolution were compared between drugs and regimen. Associations between morphologic features and VA were analyzed using multivariate modeling. MAIN OUTCOME MEASURES Resolution rates of IRC, SRF, and PED, and associations between morphology and VA. RESULTS At baseline, the proportions of eyes with IRC, SRF, and PED were balanced between the aflibercept and ranibizumab groups. At week 12, IRC resolved in 50% of eyes with both agents. Subretinal fluid resolved in 70% of pooled aflibercept-treated eyes and in 59% of ranibizumab-treated eyes, and PED resolved in 29% and 24% of pooled aflibercept-treated eyes and ranibizumab-treated eyes, respectively. At week 52, IRC resolved in 57% (aflibercept Q4wks), 50% (aflibercept Q8wks), and 52% (ranibizumab) of patients; SRF resolved in 75% (both aflibercept Q4wks/Q8wks) and 66% (ranibizumab) of patients; and PED resolved in 40% (aflibercept Q4wks), 34% (aflibercept Q8wks), and 28% (ranibizumab) of patients. During fixed dosing (weeks 12-52) all exudative features showed synchronized fluctuations after treatment-free visits in the Q8wks aflibercept regimen. During pro re nata dosing (weeks 52-96), greater proportions of patients showed recurrent fluid in all treatment arms. Presence of IRC was generally associated with lower VA at baseline, which translated into poorer final VA outcomes. CONCLUSIONS Fluid resolution in all compartments was consistently greater for aflibercept Q4wks than for aflibercept Q8wks and ranibizumab. At week 52, Q8wks aflibercept-treated eyes were, on average, as dry as or drier than with ranibizumab despite the extended treatment interval. Independent of agent or regimen, preexisting morphologic features of the retina at baseline markedly influenced VA outcomes.

[1]  Gerald Liew,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.

[2]  Georg Langs,et al.  Spatio-Temporal Signatures to Predict Retinal Disease Recurrence , 2015, IPMI.

[3]  K Bailey Freund,et al.  Do We Need a New Classification for Choroidal Neovascularization in Age-Related Macular Degeneration? , 2010, Retina.

[4]  William J Feuer,et al.  QUANTITATIVE CHANGES IN RETINAL PIGMENT EPITHELIAL DETACHMENTS AS A PREDICTOR FOR RETREATMENT WITH ANTI-VEGF THERAPY , 2013, Retina.

[5]  Bianca S. Gerendas,et al.  Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration. , 2016, JAMA ophthalmology.

[6]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[7]  Christian Simader,et al.  Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy , 2014, British Journal of Ophthalmology.

[8]  Christian Simader,et al.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.

[9]  Georg Langs,et al.  Predicting Semantic Descriptions from Medical Images with Convolutional Neural Networks , 2015, IPMI.

[10]  Christian Simader,et al.  Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. , 2015, Ophthalmology.

[11]  Francesco Bandello,et al.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) , 2014, British Journal of Ophthalmology.

[12]  Glenn J Jaffe,et al.  Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. , 2014, Ophthalmology.

[13]  Christian Simader,et al.  Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres , 2008, British Journal of Ophthalmology.

[14]  Glenn J Jaffe,et al.  Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. , 2013, Ophthalmology.

[15]  U. Schmidt-Erfurth,et al.  A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration , 2016, Progress in Retinal and Eye Research.